Harrow, Inc. announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non-preserved, twice-daily (BID) dosed prescription drug based on a ?water-free? semifluorinated alkane eyedrop technology, is now available in the U.S. ? and includes a 100% Money-Back Guarantee program.

VEVYE, uniquely dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both the signs and symptoms of dry eye disease (DED). Dry eye disease (DED) is a common condition that occurs when the eyes do not produce enough tears or when the tears evaporate too quickly, and it is often associated with chronic inflammation. Untreated DED can lead to discomfort such as stinging, burning or blurry vision, and chronic DED can interfere with daily activities like reading and using a computer.

More serious consequences include increased risk of eye infections and damage to the surface of the eye, which can potentially result in serious vision problems and even loss of sight. Causes of dry eye are varied and can include aging, certain medications, medical conditions, or environmental factors such as increased screen time and exposure to pollutants, all of which are contributing to a forecast of continued significant increase in DED. According to a 2020 report from Market Scope, DED affects more than 38 million Americans.

In addition, 92% of this patient population remains un- or under-treated due to limited efficacy and poor tolerability of existing prescription and non-prescription choices.